Infant Whole-Cell Versus Acellular Pertussis Vaccination in 1997 to 1999 and Risk of Childhood Hospitalization for Food-Induced Anaphylaxis: Linked Administrative Databases Cohort Study

J Allergy Clin Immunol Pract. 2024 Mar;12(3):670-680. doi: 10.1016/j.jaip.2023.12.048. Epub 2024 Jan 4.

Abstract

Background: Evidence suggests that children who had received an initial priming dose of whole-cell pertussis (wP) vaccine, rather than acellular pertussis (aP) vaccine, had a lower risk of developing IgE-mediated food allergy, the most common cause of anaphylaxis-related hospital presentations of childhood.

Objective: To assess the association between wP versus aP vaccination in infancy and subsequent hospital presentations for anaphylaxis.

Methods: This study was preregistered under PMID 34874968. Perinatal records for a cohort of New South Wales-born children (1997-1999) receiving their first dose of pertussis-containing vaccine before age 4 months were probabilistically linked to hospital and immunization records. We used adjusted Cox models to estimate hazard ratios (aHRs) and 95% CIs for anaphylaxis-coded hospitalizations.

Results: There were 218,093 New South Wales-born children who received a first dose of wP or aP before age 4 months. Among these children, 86 experienced at least one hospitalization for food-induced anaphylaxis at age 5-15 years (range of events per patient, one to three). The person-time of follow-up was 1,476,969 years, and 665,519 years for children vaccinated with wP as a first dose (wP-1 children) and aP as a first dose (aP-1 children), respectively. The incidence rates for first hospitalization for food anaphylaxis were 3.5 (95% CI, 2.6-4.6) and 5.1 (95% CI, 3.5-7.1) per 100,000 child-years among wP-1 children and aP-1 children, respectively (aHR for wP vs aP = 0.47; 95% CI, 0.26-0.83). For first admission for venom anaphylaxis, the incidence rate was 4.9 (95% CI, 3.9-6.2) per 100,000 child-years among wP-1 children and 5.1 (95% CI, 3.5-7.1) per 100,000 child-years among aP-1 children (aHR for wP vs aP = 0.92; 95% CI, 0.53-1.60), and for all-cause anaphylaxis, the incidence rate was 10.6 (95% CI, 9.0-12.4) per 100,000 child-years among wP-1 children and 12.8 (95% CI, 10.2-15.8) per 100,000 child-years among aP-1 children (aHR for wP vs aP = 0.92; 95% CI, 0.53-1.60).

Conclusion: Vaccination with wP in infancy was associated with a lower risk of hospitalizations for food-induced anaphylaxis (and therefore severe IgE-mediated food allergy) occurring in childhood.

Keywords: Acellular pertussis vaccine; Anaphylaxis; Food allergy; Whole-cell pertussis vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetazolamide / analogs & derivatives*
  • Anaphylaxis* / epidemiology
  • Child, Preschool
  • Cohort Studies
  • Food Hypersensitivity* / epidemiology
  • Hospitalization
  • Humans
  • Immunization, Secondary
  • Immunoglobulin E
  • Infant
  • Pertussis Vaccine
  • Tetracyclines*
  • Transcription Factor AP-1
  • Vaccination
  • Whooping Cough* / prevention & control

Substances

  • WP 1
  • Transcription Factor AP-1
  • Pertussis Vaccine
  • Immunoglobulin E
  • Acetazolamide
  • Tetracyclines